| Trial ID: | L0171 |
| Source ID: | NCT03445208
|
| Associated Drug: |
BMS-986036
|
| Title: |
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Hepatic Cirrhosis|Liver Fibrosis|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: BMS-986036
|
| Outcome Measures: |
Maximum observed serum concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)]|Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(0-inf)]|Number of injection site reactions|Number of adverse events (AE)|Number of serious adverse events (SAE)|Number of AEs leading to discontinuation|Number of deaths|Serum biomarker antibody concentration
|
| Sponsor/Collaborators: |
Bristol-Myers Squibb
|
| Gender: |
All
|
| Age: |
21 Years to 55 Years ?? (Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
30
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
February 14, 2018
|
| Completion Date: |
May 2, 2018
|
| Results First Posted: |
--
|
| Last Update Posted: |
March 19, 2020
|
| Locations: |
PRA Health Sciences, Salt Lake City, Utah, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT03445208
|
